NEKTAR THERAPEUTICSNKTREarnings & Financial Report
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...
NKTR Q4 FY2025 Key Financial Metrics
Revenue
$21.8M
Gross Profit
N/A
Operating Profit
$-27.7M
Net Profit
$-36.1M
Gross Margin
N/A
Operating Margin
-126.9%
Net Margin
-165.4%
YoY Growth
-25.3%
EPS
$-4.67
NEKTAR THERAPEUTICS Q4 FY2025 Financial Summary
NEKTAR THERAPEUTICS reported revenue of $21.8M (down 25.3% YoY) for Q4 FY2025, with a net profit of $-36.1M (down 596.9% YoY) (-165.4% margin).
Key Financial Metrics
| Total Revenue | $21.8M |
|---|---|
| Net Profit | $-36.1M |
| Gross Margin | N/A |
| Operating Margin | -126.9% |
| Report Period | Q4 FY2025 |
NEKTAR THERAPEUTICS Annual Revenue by Year
NEKTAR THERAPEUTICS annual revenue history includes year-by-year totals (for example, 2025 revenue was $55.2M).
NEKTAR THERAPEUTICS Quarterly Revenue & Net Profit History
NEKTAR THERAPEUTICS results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.8M | -25.3% | $-36.1M | -165.4% |
| Q3 FY2025 | $11.8M | -51.1% | $-35.5M | -301.3% |
| Q2 FY2025 | $11.2M | -52.4% | $-41.6M | -372.2% |
| Q1 FY2025 | $10.5M | -51.7% | $-50.9M | -486.4% |
| Q4 FY2024 | $29.2M | +22.1% | $7.3M | 24.9% |
| Q3 FY2024 | $24.1M | -0.1% | $-37.1M | -153.6% |
| Q2 FY2024 | $23.5M | +14.6% | $-52.4M | -222.9% |
| Q1 FY2024 | $21.6M | +0.2% | $-36.8M | -170.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.6M | $23.5M | $24.1M | $29.2M | $10.5M | $11.2M | $11.8M | $21.8M |
| YoY Growth | 0.2% | 14.6% | -0.1% | 22.1% | -51.7% | -52.4% | -51.1% | -25.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $396.0M | $343.3M | $308.0M | $303.9M | $256.2M | $207.5M | $301.3M | $280.4M |
| Liabilities | $269.3M | $263.6M | $259.1M | $243.1M | $242.5M | $231.7M | $216.3M | $190.6M |
| Equity | $126.7M | $79.7M | $48.9M | $60.7M | $13.7M | $-24.2M | $85.1M | $89.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-47.9M | $-37.7M | $-43.9M | $-46.2M | $-49.1M | $-45.7M | $-48.8M | $-65.0M |